AstraZeneca and Daiichi Sankyo are preparing regulatory filings that could make their HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and HER2 ...

Proton therapy is a type of radiation therapy that’s more targeted than traditional radiation therapy. It may lower the risk of damage to surrounding tissue. However, more long-term research is ...

Breast cancer doesn’t always produce symptoms in the early stages, although some people receive a diagnosis after noticing a lump. In one rare type, called inflammatory breast cancer, a rash ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...